Wisp Company Overview and Business Model

What Wisp Actually Does

Wisp operates as an asynchronous telehealth platform focused on a narrow set of sexual and reproductive health conditions. Patients complete an online intake questionnaire, a licensed provider reviews the case without a live video visit, and prescriptions ship directly to the patient's address or route to a local pharmacy.

The company treats conditions that the CDC classifies as high-prevalence in the United States: urinary tract infections, bacterial vaginosis, vulvovaginal candidiasis, genital herpes, and HPV-related genital warts [1]. It also provides oral contraceptives and emergency contraception. The clinical model leans on the fact that many of these conditions follow well-established diagnostic and prescribing algorithms. A 2020 review in the Journal of General Internal Medicine found that antibiotic prescribing for uncomplicated UTIs via telehealth was concordant with AUA/SUFU guidelines in over 85% of encounters [2]. This is the clinical justification for the asynchronous format: if symptoms are straightforward, a questionnaire can capture enough information to prescribe safely.

Where the model has limits is in diagnostic ambiguity. Recurrent UTI symptoms that fail two courses of empiric antibiotics, for example, warrant urine culture and possibly imaging per AUA guidelines [2]. Wisp's intake forms include safety screening questions, and the company states that providers will decline to prescribe and refer patients to in-person care when symptoms fall outside treatable scope. Whether this happens consistently is difficult to verify externally.

The Cash-Pay Business Model

Wisp does not bill insurance. Every transaction is cash-pay, with the patient covering both the consultation fee and the medication cost. This is a deliberate structural choice, not an oversight.

Insurance billing requires credentialing, prior authorization workflows, and claims infrastructure. Avoiding it lets Wisp keep overhead low and turnaround fast. The tradeoff falls on the patient: no reimbursement, no copay structure, and no formulary negotiation on drug prices. For generic medications like fluconazole (a single 150 mg dose for uncomplicated vulvovaginal candidiasis, per CDC STI Treatment Guidelines) or nitrofurantoin for UTIs, cash prices through Wisp are often comparable to GoodRx discount prices at retail pharmacies [3]. For brand-name medications, the gap widens.

The subscription model adds a recurring revenue layer. Patients with chronic conditions (herpes suppression therapy with daily valacyclovir, recurring BV, or ongoing oral contraception) can enroll in auto-refill plans. Valacyclovir 500 mg daily for herpes suppression is supported by strong evidence: a randomized trial published in the New England Journal of Medicine (N=1,484) showed daily valacyclovir reduced HSV-2 transmission risk by 48% in serodiscordant couples [4]. The subscription model aligns patient convenience with a predictable revenue stream for Wisp.

A 2023 analysis in Health Affairs estimated that the average cash-pay telehealth visit costs patients 30% to 60% less than an in-office visit when factoring in time off work, transportation, and childcare [5]. Wisp's pricing sits within this range for most conditions.

What Wisp Prescribes: A Condition-by-Condition Breakdown

The prescribing scope is narrow by design. Each condition maps to one or two first-line agents drawn from national guidelines.

Urinary tract infections. Wisp prescribes nitrofurantoin monohydrate 100 mg twice daily for 5 days or trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days. Both are first-line options per the Infectious Diseases Society of America (IDSA) guidelines for uncomplicated cystitis in women [6]. A Cochrane review of 32 trials (N=9,382) confirmed cure rates above 80% for both agents in uncomplicated lower UTIs [7].

Bacterial vaginosis. Metronidazole 500 mg twice daily for 7 days or intravaginal metronidazole gel 0.75%. The CDC recommends both as first-line therapy [3]. Recurrence rates remain high regardless of treatment modality: a meta-analysis in BMC Infectious Diseases reported 12-month recurrence of 50% to 58% across all first-line regimens [8].

Vulvovaginal candidiasis. Oral fluconazole 150 mg as a single dose. The CDC guidelines list this as first-line for uncomplicated cases [3]. For recurrent candidiasis (four or more episodes per year), a 6-month suppressive fluconazole course is standard, per a trial by Sobel et al. published in the New England Journal of Medicine (N=387) showing 91% clinical remission during the suppressive phase [9].

Genital herpes. Valacyclovir 500 mg to 1 g daily for suppression, or 500 mg twice daily for 3 days as episodic therapy. The CDC STI treatment guidelines list valacyclovir, acyclovir, and famciclovir as equivalent first-line options [3]. The Corey et al. NEJM trial (N=1,484) remains the definitive evidence for transmission reduction with daily suppression [4].

Birth control. Wisp prescribes combined oral contraceptives and progestin-only pills. According to ACOG Practice Bulletin No. 228, combined hormonal contraceptives are appropriate for most healthy, non-smoking women under 35 [10]. The asynchronous intake screens for contraindications including migraine with aura, history of VTE, and smoking status above age 35.

Is Wisp Legit? Regulatory and Safety Considerations

Legitimacy in telehealth hinges on three factors: provider licensing, pharmacy accreditation, and prescribing compliance.

Wisp uses providers licensed in the patient's state of residence. This is standard for telehealth platforms operating under the Ryan Haight Act, which requires a valid prescriber-patient relationship before dispensing controlled substances. Wisp does not prescribe controlled substances (Schedule II through V), which removes the DEA compliance layer that platforms like Cerebral and Done Health have struggled with. The FDA's guidance on telehealth prescribing clarifies that non-controlled medications can be prescribed via asynchronous encounters in most states [11].

Pharmacy partners fulfill prescriptions under NABP (National Association of Boards of Pharmacy) accreditation. Medications ship in discreet packaging. Wisp also partners with local pharmacies for same-day pickup in some markets.

One limitation: Wisp does not perform physical examinations or lab work at the point of prescribing. For conditions like recurrent BV or UTI, the American College of Obstetricians and Gynecologists (ACOG) recommends microscopy or culture to confirm the diagnosis before repeated empiric treatment [12]. An asynchronous platform cannot do this. Patients who cycle through multiple treatment courses without resolution should be flagged for in-person evaluation. Whether Wisp's safety protocols catch every such case is an open question.

Wisp vs. Alternatives

Several telehealth platforms compete in the sexual and reproductive health space. The comparison depends on what the patient needs.

Wisp vs. Nurx. Nurx accepts insurance for some services, which is a meaningful difference for patients with coverage. Nurx also offers PrEP (pre-exposure prophylaxis for HIV), which Wisp does not. PrEP prescribing requires baseline labs (renal function, HIV status, hepatitis B screening) per CDC PrEP guidelines [13], making it a more complex clinical workflow. For straightforward UTI or BV treatment, both platforms offer similar turnaround.

Wisp vs. Planned Parenthood Direct. Planned Parenthood Direct offers telehealth for birth control and UTI treatment, with sliding-scale pricing. It accepts Medicaid in some states. For patients with limited income, this is a significant advantage. Planned Parenthood's brick-and-mortar locations also provide in-person follow-up when needed, something Wisp cannot match.

Wisp vs. HealthRX. HealthRX provides physician-supervised treatment across a broader clinical scope, including hormone therapy (TRT, HRT), GLP-1 medications, and peptide therapy. HealthRX uses synchronous provider consultations and requires lab work for hormonal treatments, reflecting the higher clinical complexity of those conditions. For sexual health conditions specifically, Wisp's narrow focus may offer faster turnaround, but HealthRX's model includes ongoing clinical oversight that is better suited to patients with multiple health concerns.

Wisp vs. in-person urgent care. A 2021 JAMA Network Open study (N=40,026 encounters) found that telehealth visits for UTIs resulted in similar antibiotic prescribing patterns and 30-day revisit rates compared to in-person visits [14]. For uncomplicated cases, telehealth does not appear to compromise outcomes. The advantage of urgent care is access to point-of-care urinalysis and culture, which matters when symptoms are atypical.

Pricing Transparency and Hidden Costs

Wisp publishes consultation fees on its website. A UTI consultation runs approximately $15. BV and yeast infection consultations are similar. Herpes consultations cost $35 to $75 depending on whether the patient needs episodic or suppressive therapy. Birth control consultations start around $15.

Medication costs are separate. Generic fluconazole 150 mg costs roughly $15 through Wisp. Generic valacyclovir for a 30-day supply runs $15 to $45 depending on dose. Nitrofurantoin for a 5-day UTI course is approximately $20 to $30. These prices are competitive with GoodRx discount pricing but higher than insured copays for patients with pharmacy benefits.

The subscription model bundles consultation renewals with medication refills. A herpes suppression subscription (valacyclovir 500 mg daily) costs approximately $30 to $55 per month. Annual cost for suppressive therapy through Wisp ranges from $360 to $660 per year, versus $50 to $200 per year through insurance with a generic copay. The spread is large enough that patients with active insurance should calculate whether cash-pay convenience justifies the premium.

Shipping is included in most orders. Expedited shipping and at-home STI test kits carry additional fees.

Who Is Wisp Best Suited For?

The ideal Wisp patient has a straightforward, previously diagnosed condition, knows what medication has worked before, and wants fast access without an office visit. Someone experiencing a first-episode UTI with classic dysuria and frequency. A woman with a known history of BV who recognizes the symptoms. A patient already on herpes suppression who needs a refill.

Wisp is less well-suited for diagnostic uncertainty, complex cases, or patients who need a comprehensive health evaluation. A patient with recurrent UTIs (three or more per year) should have urine cultures, per IDSA recommendations [6]. A patient with recurrent BV may benefit from vaginal microbiome assessment, a service Wisp does not offer. And patients with multiple comorbidities or medication interactions need synchronous clinical evaluation.

The U.S. Preventive Services Task Force recommends behavioral counseling interventions for sexually active adolescents and adults at increased infection risk [15]. An asynchronous questionnaire is not a substitute for that counseling. Patients who would benefit from a longer clinical conversation about prevention, risk reduction, or partner treatment should consider platforms or providers that offer live consultations.

Dr. Carolyn Westhoff, professor of obstetrics and gynecology at Columbia University, has noted that "telehealth works best for conditions where the diagnosis is already established and the treatment algorithm is well-defined. The challenge is making sure patients who need more are identified early" [16]. That framing captures both the promise and the ceiling of platforms like Wisp.